Evaluating and Comparing the Adherence to Immediate- Release Tacrolimus (Prograf®) Versus Extended-Release Tacrolimus (Advagraf®) in Kidney Transplant Recipients

Authors

  • Mojtaba Shafiekhani Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran Author https://orcid.org/0000-0001-8661-1838
  • Mohammad Mahdi Mahmoudi Shiraz Transplant Center, Abu-Ali Sina Hospital, Shiraz University of Medical Sciences, Shiraz, Iran Author
  • Maryam Moghadasi Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran Author
  • Jamshid Roozbeh Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran Author https://orcid.org/0000-0002-4268-1727
  • Nakisa Rasaei Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran Author https://orcid.org/0000-0001-8568-8550
  • Marziyeh Doostfatemeh Department of Biostatistics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran Author
  • Mahkameh Moradi-Mehrabadi epartment of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran Author
  • Ibrahim Almenweer Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Damascus University, Damascus, Syria Author
  • Iman Karimzadeh Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. AND Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Author https://orcid.org/0000-0002-8956-4528

DOI:

https://doi.org/10.61882/ijkd.20.5.9515

Keywords:

Tacrolimus, Kidney transplantation, Medication adherence, Prograf, Advagraf

Abstract

Introduction. This  study  compared  adherence  rates  between immediate-release  tacrolimus  (Prograf®)  and  extended-release tacrolimus  (Advagraf®)  formulations  in  adult  kidney  transplant recipients in Iran. It is the first such comparison conducted in the country.
Methods. This  prospective,  observational  cohort  study  was conducted among adult kidney transplant recipients in Shiraz, Iran. Adherence was assessed using the Basel Assessment of Adherence to Immunosuppressive Medications Scale (BAASIS) via self-report during face-to-face or telephone interviews at baseline (month zero) and six months. Intrapatient variability (IPV) of tacrolimus trough levels  was  calculated  and  compared  between  groups.  The  study also evaluated the risk factors associated with non-adherence and their potential impact on clinical outcomes.
Results. One  hundred  and  ten  patients  (57  cases  in  the  Prograf® group  as  twice  daily;  53  cases  in  the  Advagraf® group  as  once daily)  completed  six  month  follow-up.  At  month  six,  adherence rates  were  63.16%  in  the  Prograf® group  versus  81.13%  in  the Advagraf® group (P = .04). Apart from correct dosing, all adherence parameters decreased significantly from baseline in both groups. The  most  common  reason  for  non-adherence  was  forgetfulness in  the  Prograf® group  and  medication  shortages/unavailability in  the  Advagraf® group.  IPV  was  lower  in  the  Advagraf® group (13.62 ± 8.07%) versus the Prograf® group (18.15 ± 13.18%), althoughthis difference was not statistically significant (P = .10). Conclusion. Extended-release  tacrolimus  (Advagraf®)  was associated  with  significantly  better  adherence  compared  to  the immediate-release formulation (Prograf®). These findings highlight the importance of once-daily formulations in enhancing adherence in postkidney transplantation care.

Downloads

Download data is not yet available.

References

1. Berquist RK, Berquist WE, Esquivel CO, Cox KL, Wayman KI, Litt IF. Non-adherence to post-transplant care: prevalence, risk factors and outcomes in adolescent liver transplant recipients. Pediatr Transplant. 2008;12(2):194- 200.

2.Zachciał J, Uchmanowicz I, Czapla M, Krajewska M, Banasik M. The Association between Psychosocial

and Age-Related Factors with Adherence to Immunosuppressive Therapies after Renal Transplantation. J Clin Med. 2022 24;11(9):2386.

3. Bowman LJ, Brennan DC. The role of tacrolimus in renal transplantation. Expert Opin Pharmacother.

2008;9(4):635-43.

4. Shafiekhani M, Shahabinezhad F, Niknam T, et al. Evaluation of the therapeutic regimen in COVID-19 in transplant patients: where do immunomodulatory and antivirals stand? Virol J. 2021;18(1):228.

5. Chisholm MA, Mulloy LL, DiPiro JT. Comparing renal transplant patients’ adherence to free cyclosporine

and free tacrolimus immunosuppressant therapy. Clin Transplant. 2005;19(1):77-82.

6. Godinas L, Dobbels F, Hulst L, et al. Once daily tacrolimus conversion in lung transplantation: A prospective study on safety and medication adherence. J Heart Lung Transplant. 2021;40(6):467-77.

7. Bentata Y. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity. Artif Organs. 2020;44(2):140-52.

8. Javed M, Sanghera A, Khan AA, Nagpal R, Butler K,Hobill A, Gage A, Karst F, Needleman A, Hmun M, Thal

N, Shirling G, Fernando R, Jones G, Harber M, Evans RDR. Tacrolimus intrapatient variability and rejection are associated with inferior allograft outcomes after kidney transplantation. Front Nephrol. 2025 Dec 12;5:1666191. doi: 10.3389/fneph.2025.1666191.

9. Nafar M, Keshtkari S, Ziaie S, Firouzan A, Borumandnia N, Dalili N, Poorrezagholi F, Samadian F, Samavat S. Tacrolimus Intrapatient Variability on Graft Outcomes

in Adherent Renal Transplantation Patients: A Cross- Sectional Study. Iran J Kidney Dis. 2024 May;18(3):187- doi: 10.52547/54drw293.

10.Kuypers DR, Peeters PC, Sennesael JJ, Kianda MN, Vrijens B, Kristanto P, Dobbels F, Vanrenterghem Y, Kanaan N; ADMIRAD Study Team. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation. 2013 Jan 27;95(2):333-40.

11. Riani NW, Widiana IG, Kandarini Y. WCN26-8039 COMPARATIVE EFFICACY, SAFETY, AND ADHERENCE OF ONCE-DAILY VERSUS TWICE-DAILY TACROLIMUSIN ADULT KIDNEY TRANSPLANT RECIPIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS. KidneyInternational Reports. 2026 Apr 1;11(4).

12. Moradi O, Karimzadeh I, Davani-Davari D, Shafiekhani M, Sagheb MM. Pattern and associated factors of adherence to immunosuppressive medications in kidney transplant recipients at a referral center in Iran. Patient Prefer Adherence. 2019 8;13:729-38.

13. Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737-49.

14. Dobbels F, Berben L, Geest SD, et al. The psychometric properties and practicability of self-report instruments to identify medication nonadherence in adult transplant patients: a systematic review. Transplantation.2010;90(2):205-19.

15.Morais MC, Soares ME, Costa G, et al. Impact of tacrolimus intra-patient variability in adverse outcomes after organ transplantation. World J Transplant.2023;13(5):254-63.

16. Elnaem MH, Irwan NA, Abubakar U, Syed Sulaiman SA, Elrggal ME, Cheema E. Impact of Medication Regimen Simplification on Medication Adherence and Clinical Outcomes in Patients with Long-Term Medical Conditions. Patient Prefer Adherence. 2020;14:2135-45.

17. Eberlin M, Otto G, Krämer I. Increased medication compliance of liver transplant patients switched

from a twice-daily to a once-daily tacrolimus-based immunosuppressive regimen. Transplant Proc.

2013;45(6):2314-20.

18. Abedini S, Gøransson L, Cockburn E, Kilany S, Holdaas H. Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study. Transplant Direct. 2018 Feb 2;4(2):e338.

19. Fellström B, Holmdahl J, Sundvall N, Cockburn E, Kilany S, Wennberg L. Adherence of Renal Transplant

Recipients to Once-daily, Prolonged-Release and Twice- daily, Immediate-release Tacrolimus-based egimens in a Real-life Setting in Sweden. Transplant Proc. 2018;50(10):3275-82.

20. Lehner LJ, Reinke P, Hörstrup JH, et al. Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf™) in kidney transplant patients in Germany: A multicenter, noninterventional study. Clin Transplant. 2018;32(1).

21. Paterson TS, Demian M, Shapiro RJ, Thornton WL. Impact of once-versus twice-daily tacrolimus dosing on medication adherence in stable renal transplant recipients: a Canadian single-center randomized controlled trial. CanJ Kidney Health Dis. 2019;6:2054358119867993.

22.Coste G, Lemaitre F. The Role of Intra-Patient Variabilityof Tacrolimus Drug Concentrations in Solid Organ Transplantation: A Focus on Liver, Heart, Lung and Pancreas. Pharmaceutics. 2022;14(2):379.

23.Larpparisuth N, Skulratanasak P, Vongwiwatana A, Premasathian N. Effect on Dosage Change and

Intrapatient Variability After Conversion From Twice-Daily to Once-Daily Tacrolimus Among Thai Kidney Transplant Patients With and Without CYP3A4/5 Inhibitors.Transplant Proc. 2019;51(8):2620-3.

24.Brunet M, Pastor-Anglada M. Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics. Pharmaceutics. 2022;14(9):1755.

25. Ganjali R, Ghorban Sabbagh M, Nazemiyan F,et al. Factors Associated With Adherence To Immunosuppressive Therapy And Barriers In Asian Kidney Transplant Recipients. Immunotargets Ther. 2019;8:53-62.

26. Krämer BK, Albano L, Banas B, et al. Efficacy of Prolonged- and Immediate-release Tacrolimus in

Kidney Transplantation: A Pooled Analysis of Two Large, Randomized, Controlled Trials. Transplant Proc.2017;49(9):2040-9.

27. Guirado L, Cantarell C, Franco A, et al. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. Am J Transplant. 2011;11(9):1965-71.

Downloads

Published

2026-10-19

Data Availability Statement

The data supporting this study's findings are available from the corresponding author upon reasonable request.

Issue

Section

ORIGINAL | Transplantation

How to Cite

Evaluating and Comparing the Adherence to Immediate- Release Tacrolimus (Prograf®) Versus Extended-Release Tacrolimus (Advagraf®) in Kidney Transplant Recipients. (2026). Iranian Journal of Kidney Diseases, 20(5), 319-331. https://doi.org/10.61882/ijkd.20.5.9515

Similar Articles

1-10 of 638

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 > >>